COBI

(redirected from cobicistat)
Also found in: Medical.
AcronymDefinition
COBICobicistat (pharmacoenhancer)
COBIComunidad y Biodiversidad (Spanish: Community and Biodiversity; Mexico)
COBICity of Bainbridge Island (Washington state)
COBICollege of Business and Industry
COBIConnection-Oriented Bearer-Independent
COBIClinician's Overall Burden Index (social work)
COBICardiac Output Measured by Bioimpedance (cardiology)
References in periodicals archive ?
Moreover, it was shown when ritonavir or cobicistat were not used, there was only marginal difference in safety between TDF and TAF.
Miami, FL, April 11, 2019 -- The Janssen Pharmaceutical Companies of Johnson & Johnson unveiled new 48-week data for SYMTUZA[R] (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg D/C/F/TAF) showing that a high proportion of HIV patients achieved an undetectable viral load through 48 weeks after rapidly starting SYMTUZA[R].
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
PIs, primarily darunavir (DRV), together with a pharmacokinetic enhancer (cobicistat [c] or ritonavir [r]), are recommended for HIV-infected individuals with drug-resistant virus and may be considered for those who are poorly adherent to medication.
A post-mortem examination conducted by pathologist Dr Tom Hockey confirmed there was cocaine and Cobicistat - a drug used to treat HIV - detected in the body.
The number of cases described is small but the risk is probably significant for people on ritonavir and cobicistat treatment.
Second, in this study protease-inhibitors were boosted with ritonavir and now cobicistat is the booster agent.
Ritonavir and cobicistat both inhibit the metabolic pathway that breaks down methamphetamine; using meth with either of those drugs can increase meth concentrations by up to 10-fold, a combination that has killed many patients.
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV1 infection: A randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.